John C. McKew Ph.D.
Net Worth

Last updated:

What is John C. McKew Ph.D. net worth?

The estimated net worth of Dr. John C. McKew Ph.D. is at least $3,084,026 as of 2 Aug 2023. He has earned $92,066 from insider trading and has received compensation worth at least $2,991,960 in Lumos Pharma, Inc..

What is the salary of John C. McKew Ph.D.?

Dr. John C. McKew Ph.D. salary is $747,990 per year as Chief Scientific Officer & Pres in Lumos Pharma, Inc..

How old is John C. McKew Ph.D.?

Dr. John C. McKew Ph.D. is 61 years old, born in 1964.

What stocks does John C. McKew Ph.D. currently own?

As insider, Dr. John C. McKew Ph.D. owns shares in one company:

Company Title Shares Price per share Total value
Lumos Pharma, Inc. (LUMO) Chief Scientific Officer & Pres 18,707 $0 $0

What does Lumos Pharma, Inc. do?

Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.

John C. McKew Ph.D. insider trading

Lumos Pharma, Inc.

Dr. John C. McKew Ph.D. has made 7 insider trades between 2021-2023, according to the Form 4 filled with the SEC. Most recently he sold 3,407 units of LUMO stock worth $10,919 on 2 Aug 2023.

The largest trade he's ever made was exercising 3,407 units of LUMO stock on 2 Aug 2022. As of 2 Aug 2023 he still owns at least 18,707 units of LUMO stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Common Stock 3,407 $3.21 $10,919
Sale
Common Stock 2,214 $3.27 $7,240
Sale
Common Stock 439 $3.53 $1,550
Sale
Common Stock 3,407 $8.11 $27,631
Sale
Common Stock 169 $7.62 $1,288
Sale
Common Stock 2,214 $8.32 $18,420
Sale
Common Stock 2,214 $11.3 $25,018

Lumos Pharma key executives

Lumos Pharma, Inc. executives and other stock owners filed with the SEC: